PPARÎ³ signaling and emerging opportunities for improved therapeutics.

Wang, Shuibang; Dougherty, Edward J; Danner, Robert L

Wang, Shuibang; Dougherty, Edward J; Danner, Robert L.

Affiliation

Wang S; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: swang@cc.nih.gov.
Dougherty EJ; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Danner RL; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: rdanner@nih.gov.

Pharmacol Res ; 111: 76-85, 2016 09.

Article in En | MEDLINE | ID: mdl-27268145

Subject(s)

Cardiovascular Agents/therapeutic use; Hypoglycemic Agents/therapeutic use; PPAR gamma/agonists; Signal Transduction/drug effects; Animals; Cardiovascular Agents/adverse effects; Drug Design; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases/metabolism; Fatty Acids/metabolism; Humans; Hypoglycemic Agents/adverse effects; Ligands; Molecular Targeted Therapy; Nitric Oxide/metabolism; PPAR gamma/metabolism; Phosphorylation; Protein Processing, Post-Translational; Receptors, G-Protein-Coupled/metabolism; p38 Mitogen-Activated Protein Kinases/metabolism

Key words

E1A binding protein p300 (EP300); G protein-coupled receptor 40 (GPR40); P38 mitogen-activated protein kinase (p38 MAPK); PPARÎ³ co-activator-1alpha (PGC-1α); Peroxisome proliferator-activated receptor gamma (PPARÎ³); Thiazolidinediones (TZDs)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Cardiovascular Agents / Signal Transduction / PPAR gamma / Hypoglycemic Agents Limits: Animals / Humans Language: En Journal: Pharmacol Res Journal subject: FARMACOLOGIA Year: 2016 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google